Privia Health Group, Inc.

Health Care
Medical/Nursing Services
www.priviahealth.com

Earnings Score
Moat Score

Market Cap $2.52B
PE 205
Debt $NaN
Cash $422.00M
EV $NaN
FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$12.31M
EBIT	$24.12M
ROE	2%
ROA	2%
Equity	$662.18M
Growth Stability	1
PE	205.01
PEG	-33.96
PB	3.81
P/S	1.47
Price/Cash	0.17
Net Margins	1%
Op. Margins	1%
Earnings CAGR	-6%
Sales Growth YoY	5%
Sales Growth QoQ	4%
Sales CAGR	26%
FCF CAGR	1%
Equity CAGR	52%
Earnings Stability	-0.6
Earnings Growth YoY	-41%
Earnings Growth QoQ	2%

Earnings CAGR 5Y	-6%
Sales CAGR 5Y	26%
FCF CAGR 5Y	1%
Equity CAGR 5Y	52%
Earnings CAGR 3Y	23%
Sales CAGR 3Y	23%
FCF CAGR 3Y	4%
Equity CAGR 3Y	16%
Market Cap	$2.52B
Revenue	$1.72B
Assets	$1.15B
Cash	$422.00M
Shares Outstanding	119.16M
Earnings Score	6%
Moat Score	29%
Working Capital	374.28M
Current Ratio	1.78
Shares Growth 3y	5%
Equity Growth QoQ	3%
Equity Growth YoY	12%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.

SEC Filings

Direct access to Privia Health Group, Inc. (PRVA) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Privia Health Group, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Privia Health Group, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -6%

Stability -60%

loading chart...

Privia Health Group, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Privia Health Group, Inc..

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	1%	4%	-20%	-1%	1%	1%
ROA	-	8%	-32%	-2%	3%	2%
ROE	-	21%	-42%	-2%	3%	2%

Bad Net Margins (0.78%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	0.02	0.63	0	-	-
Debt over Equity	-	0.01	0.08	0	-	-
Growth Stability	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	4%	18%	40%	22%	26%
Earnings YoY growth	-	289%	-717%	-94%	-274%	-6%
Equity YoY growth	-	37%	207%	15%	17%	52%
FCF YoY growth	-	107%	42%	-14%	71%	1%